Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
Authors:
Open Access
- 19 July 2021
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 5 (8) , e624
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Limitations of poor bone marrow aspirations (for an accurate diagnosis) despite the multimodal analytical era: A longitudinal retrospective studyAmerican Journal of Hematology, 2017
- Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic MalignanciesThe Journal of Molecular Diagnostics, 2016
- HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibBlood, 2016
- To select or not to select? The role of B‐cell selection in determining the MYD88 mutation status in Waldenström MacroglobulinaemiaBritish Journal of Haematology, 2016
- MYD88 Mutations and Response to Ibrutinib in Waldenström's MacroglobulinemiaNew England Journal of Medicine, 2015
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaNew England Journal of Medicine, 2015
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemiaBlood, 2014
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaBlood, 2013
- MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionBlood, 2013
- MYD88 L265P Somatic Mutation in Waldenström's MacroglobulinemiaNew England Journal of Medicine, 2012